Company intelligence / Profile preview

Predictive Biotech

Salt Lake City, Utah, United Statesfda.gov ↗

Ownership: Private
Development stage: Commercial

Overview

The company has faced FDA warnings regarding its CoreCyte product, which was marketed for COVID-19 without proper authorization. The FDA issued a warning letter in August 2020 stating that Predictive Biotech was marketing an unapproved biological product[3].

Therapeutic areas: OtherInfectious Diseases
Modalities: Human cell and tissue products
Industry: Biotech

Drug pipeline

3 assets

CoreCyte

Unknown

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Predictive Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Predictive Biotech.

Explore the full profile